Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma

BACKGROUND: Cutaneous melanoma is the most serious skin malignancy and new therapeutic strategies are needed for advanced melanoma. TP53 mutations are rare in cutaneous melanoma and hence activation of wild-type p53 is a potential therapeutic strategy in cutaneous melanoma. Here, we investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Chiao-En, Esfandiari, Arman, Ho, Yi-Hsuan, Wang, Nan, Mahdi, Ahmed Khairallah, Aptullahoglu, Erhan, Lovat, Penny, Lunec, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830592/
https://www.ncbi.nlm.nih.gov/pubmed/29235570
http://dx.doi.org/10.1038/bjc.2017.433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830592/
https://www.ncbi.nlm.nih.gov/pubmed/29235570
http://dx.doi.org/10.1038/bjc.2017.433

Ejemplares similares